@entity461 plus @entity561 in XXXX : a meta-analysis of randomized controlled trials.

@entity1 @entity353 @entity561 @entity170 @entity1555 @entity461
BACKGROUND: @entity461 ( @entity461 ) increases both bone formation ( @entity1555 ) and bone resorption, whereas @entity561 reduces bone resorption. It is possible that the combination therapy of @entity461 with @entity561 will enhance their effects on @entity1555 . Therefore, we conducted this meta-analysis to evaluate the efficacy of the combination therapy of @entity461 with @entity561 in the treatment of @entity1 with @entity170 . METHODS: A comprehensive literature search of PubMed, Embase, and Web of Science was conducted to identify relative studies. Eligible studies were randomized controlled trials (RCT), which assessed the efficacy of combination therapy in @entity1 with @entity170 . The outcomes included the mean percent increases in @entity1555 of lumbar spine, femoral neck, total hip, and distal radius. @entity353 ( @entity353 ) with 95% confidence intervals (CIs) were calculated using of random-effects or fixed-effects model, depending on the heterogeneity between the included studies. RESULTS: Six RCTs with a total number of 833 @entity1 were included in this meta-analysis. The pooled estimates showed that, the combination therapy of @entity461 with @entity561 resulted in a higher mean percent change of increased @entity1555 in distal radius ( @entity353 = 2.45, 95% CI: 1.58, 3.31; P = 0.000), but not in lumbar spine ( @entity353 = -0.83, 95% CI: -3.48, 1.81; P = 0.538), femoral neck ( @entity353 = -0.99, 95% CI: -2.04, 0.07; P = 0.068), and total hip ( @entity353 = -0.06, 95% CI: -0.93, 0.81; P = 0.892). The subgroup analysis based on the dosage and schedule of @entity461 , study duration, gender of @entity1 , and anabolic agents, were conducted. And results revealed that among the @entity1 in the combination therapy group, greater increases in the spine @entity1555 were observed when the @entity461 was administered with a dosage of 20  g ( @entity353 = 2.33, 95% CI: 1.24, 3.43; P = 0.000), or the treatment duration lasted more than 12 months ( @entity353 = 2.23, 95% CI: 1.00, 3.47; P = 0.000), or the combination therapy was used in @entity170 @entity1 ( @entity353 = 1.58, 95% CI: 0.63, 2.53; P = 0.001). However, the combination of @entity461 of 40  g with @entity561 produced a decrease in the @entity1555 at spine ( @entity353 = -4.56, 95% CI: -7.56, -1.56; P = 0.003) and femoral neck ( @entity353 = -5.82, 95% CI: -9.91, -1.72; P = 0.005). CONCLUSION: Our findings indicated that the addition of @entity561 to @entity461 in the treatment of @entity170 , reduced the ability of @entity461 therapy to increase the @entity1555 at the lumbar spine, femoral neck, and total hip.
